Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The transaction generates upfront cash proceeds of $442 million for Syncona's holding in Gyroscope
Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades
Data from the Phase 2b QUASAR Induction Study showed approximately 60% of patients achieved the primary endpoint of clinical response, and approximately 30% showed endoscopic improvement with TREMFYA treatment compared with placebo
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Darolutamide is developed jointly by Bayer and Orion Corporation
Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Subscribe To Our Newsletter & Stay Updated
